Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 138

1.

Docetaxel-resistance in prostate cancer: evaluating associated phenotypic changes and potential for resistance transfer via exosomes.

Corcoran C, Rani S, O'Brien K, O'Neill A, Prencipe M, Sheikh R, Webb G, McDermott R, Watson W, Crown J, O'Driscoll L.

PLoS One. 2012;7(12):e50999. doi: 10.1371/journal.pone.0050999. Epub 2012 Dec 10.

2.

miR-34a is an intracellular and exosomal predictive biomarker for response to docetaxel with clinical relevance to prostate cancer progression.

Corcoran C, Rani S, O'Driscoll L.

Prostate. 2014 Sep;74(13):1320-34. doi: 10.1002/pros.22848. Epub 2014 Jul 22.

PMID:
25053345
3.

Molecular profiling of prostate cancer derived exosomes may reveal a predictive signature for response to docetaxel.

Kharaziha P, Chioureas D, Rutishauser D, Baltatzis G, Lennartsson L, Fonseca P, Azimi A, Hultenby K, Zubarev R, Ullén A, Yachnin J, Nilsson S, Panaretakis T.

Oncotarget. 2015 Aug 28;6(25):21740-54.

4.

Functional p53 determines docetaxel sensitivity in prostate cancer cells.

Liu C, Zhu Y, Lou W, Nadiminty N, Chen X, Zhou Q, Shi XB, deVere White RW, Gao AC.

Prostate. 2013 Mar;73(4):418-27. doi: 10.1002/pros.22583. Epub 2012 Sep 19.

5.

Interferon inducible antiviral MxA is inversely associated with prostate cancer and regulates cell cycle, invasion and Docetaxel induced apoptosis.

Brown SG, Knowell AE, Hunt A, Patel D, Bhosle S, Chaudhary J.

Prostate. 2015 Feb 15;75(3):266-79. doi: 10.1002/pros.22912. Epub 2014 Oct 18.

6.

Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity.

Domingo-Domenech J, Oliva C, Rovira A, Codony-Servat J, Bosch M, Filella X, Montagut C, Tapia M, Campás C, Dang L, Rolfe M, Ross JS, Gascon P, Albanell J, Mellado B.

Clin Cancer Res. 2006 Sep 15;12(18):5578-86.

7.

Docetaxel maintains its cytotoxic activity under hypoxic conditions in prostate cancer cells.

Forde JC, Perry AS, Brennan K, Martin LM, Lawler MP, Lynch TH, Hollywood D, Marignol L.

Urol Oncol. 2012 Nov-Dec;30(6):912-9. doi: 10.1016/j.urolonc.2010.08.015. Epub 2010 Dec 21.

PMID:
21176881
8.

Lenalidomide enhances the anti-prostate cancer activity of docetaxel in vitro and in vivo.

Henry JY, Lu L, Adams M, Meyer B, Bartlett JB, Dalgleish AG, Galustian C.

Prostate. 2012 Jun 1;72(8):856-67. doi: 10.1002/pros.21488. Epub 2011 Oct 3.

PMID:
21968939
9.

Gene expression profiling of the androgen independent prostate cancer cells demonstrates complex mechanisms mediating resistance to docetaxel.

Desarnaud F, Geck P, Parkin C, Carpinito G, Makarovskiy AN.

Cancer Biol Ther. 2011 Jan 15;11(2):204-12. Epub 2011 Jan 15.

10.

The use of LC-MS to identify differentially expressed proteins in docetaxel-resistant prostate cancer cell lines.

O'Connell K, Prencipe M, O'Neill A, Corcoran C, Rani S, Henry M, Dowling P, Meleady P, O'Driscoll L, Watson W, O'Connor R.

Proteomics. 2012 Jul;12(13):2115-26. doi: 10.1002/pmic.201100489.

PMID:
22623417
11.

Residual prostate cancer cells after docetaxel therapy increase the tumorigenic potential via constitutive signaling of CXCR4, ERK1/2 and c-Myc.

Hatano K, Yamaguchi S, Nimura K, Murakami K, Nagahara A, Fujita K, Uemura M, Nakai Y, Tsuchiya M, Nakayama M, Nonomura N, Kaneda Y.

Mol Cancer Res. 2013 Sep;11(9):1088-100. doi: 10.1158/1541-7786.MCR-13-0029-T. Epub 2013 Jun 20.

12.

Identification of candidate biomarkers of therapeutic response to docetaxel by proteomic profiling.

Zhao L, Lee BY, Brown DA, Molloy MP, Marx GM, Pavlakis N, Boyer MJ, Stockler MR, Kaplan W, Breit SN, Sutherland RL, Henshall SM, Horvath LG.

Cancer Res. 2009 Oct 1;69(19):7696-703. doi: 10.1158/0008-5472.CAN-08-4901. Epub 2009 Sep 22.

13.

Characterisation and manipulation of docetaxel resistant prostate cancer cell lines.

O'Neill AJ, Prencipe M, Dowling C, Fan Y, Mulrane L, Gallagher WM, O'Connor D, O'Connor R, Devery A, Corcoran C, Rani S, O'Driscoll L, Fitzpatrick JM, Watson RW.

Mol Cancer. 2011 Oct 7;10:126. doi: 10.1186/1476-4598-10-126.

14.

A combination of desmopressin and docetaxel inhibit cell proliferation and invasion mediated by urokinase-type plasminogen activator (uPA) in human prostate cancer cells.

Sasaki H, Klotz LH, Sugar LM, Kiss A, Venkateswaran V.

Biochem Biophys Res Commun. 2015 Aug 28;464(3):848-54. doi: 10.1016/j.bbrc.2015.07.050. Epub 2015 Jul 13.

PMID:
26182875
15.

A novel histone deacetylase inhibitor, CG200745, potentiates anticancer effect of docetaxel in prostate cancer via decreasing Mcl-1 and Bcl-XL.

Hwang JJ, Kim YS, Kim T, Kim MJ, Jeong IG, Lee JH, Choi J, Jang S, Ro S, Kim CS.

Invest New Drugs. 2012 Aug;30(4):1434-42. doi: 10.1007/s10637-011-9718-1. Epub 2011 Jul 20.

PMID:
21773733
16.

Enhancement of docetaxel-induced cytotoxicity and apoptosis by all-trans retinoic acid (ATRA) through downregulation of survivin (BIRC5), MCL-1 and LTbeta-R in hormone- and drug resistant prostate cancer cell line, DU-145.

Kucukzeybek Y, Gul MK, Cengiz E, Erten C, Karaca B, Gorumlu G, Atmaca H, Uzunoglu S, Karabulut B, Sanli UA, Uslu R.

J Exp Clin Cancer Res. 2008 Sep 12;27:37. doi: 10.1186/1756-9966-27-37.

17.

Identification of docetaxel resistance genes in castration-resistant prostate cancer.

Marín-Aguilera M, Codony-Servat J, Kalko SG, Fernández PL, Bermudo R, Buxo E, Ribal MJ, Gascón P, Mellado B.

Mol Cancer Ther. 2012 Feb;11(2):329-39. doi: 10.1158/1535-7163.MCT-11-0289. Epub 2011 Oct 25.

18.

Exosomes from triple-negative breast cancer cells can transfer phenotypic traits representing their cells of origin to secondary cells.

O'Brien K, Rani S, Corcoran C, Wallace R, Hughes L, Friel AM, McDonnell S, Crown J, Radomski MW, O'Driscoll L.

Eur J Cancer. 2013 May;49(8):1845-59. doi: 10.1016/j.ejca.2013.01.017. Epub 2013 Feb 27.

PMID:
23453937
19.

HIV-1 protease inhibitor, ritonavir: a potent inhibitor of CYP3A4, enhanced the anticancer effects of docetaxel in androgen-independent prostate cancer cells in vitro and in vivo.

Ikezoe T, Hisatake Y, Takeuchi T, Ohtsuki Y, Yang Y, Said JW, Taguchi H, Koeffler HP.

Cancer Res. 2004 Oct 15;64(20):7426-31.

20.

Novel role of Stat1 in the development of docetaxel resistance in prostate tumor cells.

Patterson SG, Wei S, Chen X, Sallman DA, Gilvary DL, Zhong B, Pow-Sang J, Yeatman T, Djeu JY.

Oncogene. 2006 Oct 5;25(45):6113-22. Epub 2006 May 1.

PMID:
16652143
Items per page

Supplemental Content

Write to the Help Desk